Icon

CAPLYTA (nda209500)- (EQ 42MG BASE,EQ 10.5MG BASE,EQ 21MG BASE)

LUMATEPERONE TOSYLATE INTRA-CELLULAR
EQ 42MG BASE,EQ 10.5MG BASE,EQ 21MG BASE
Yes No
2040-Dec-10 2024-Dec-20
None None
None No
CAPLYTA is an atypical antipsychotic indicated for the treatment of: • Schizophrenia in adults. • Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
0 0 0
Total Other Developers 14
Drugs with Suitability No
EQ 42MG BASE ** ** Up - -
EQ 10.5MG BASE ** ** - - -
EQ 21MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.